Evidence map›Paper›PMID 42653146›Full record

ReviewInternational journal of molecular sciences2026

Peripheral GABA Signaling in Metabolic Adaptation and Maladaptation.

Tolulope Peter Saliu, Adedeji O Adetunji, Johnson O Ogunsile, Hannah O Popoola, Chinyere Mary-Cynthia Ikele, Sierra N Miller, Kelly Oriakhi, Fernando Diaz, Stephen P Karaganis

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tolulope Peter SaliuDepartment of Life, Earth and Environmental Sciences, West Texas A&M University, Canyon, TX 79016, USA.ORCID 0000-0002-4857-3882
Adedeji O AdetunjiDepartment of Agriculture, University of Arkansas at Pine Bluff, Pine Bluff, AR 71602, USA.ORCID 0000-0002-6611-126X
Johnson O OgunsileMolecular Targets and Therapeutics Center, Institute of Virology, Helmholtz Munich, 85764 Neuherberg, Germany.
Hannah O PopoolaDepartment of Chemistry & Biochemistry, Miami University, Oxford, OH 45056, USA.ORCID 0000-0001-9180-5979
Chinyere Mary-Cynthia IkeleDepartment of Biology, New Mexico State University, Las Cruces, NM 88003, USA.ORCID 0000-0001-6807-7248
Sierra N MillerDepartment of Life, Earth and Environmental Sciences, West Texas A&M University, Canyon, TX 79016, USA.ORCID 0000-0002-9490-9041
Kelly OriakhiDepartment of Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
Fernando DiazDepartment of Life, Earth and Environmental Sciences, West Texas A&M University, Canyon, TX 79016, USA.
Stephen P KaraganisDepartment of Life, Earth and Environmental Sciences, West Texas A&M University, Canyon, TX 79016, USA.ORCID 0000-0002-2623-9592

Funding

National Institute of Food and Agriculture ARX01-6012
6 · The paper itself

Abstract

Peripheral γ-aminobutyric acid (GABA) signaling is emerging as a context-dependent contributor to metabolic regulation. Long recognized as the principal inhibitory neurotransmitter in the central nervous system, GABA's role as an important signal in peripheral tissues is recently getting attention. This expanded view raises a central question: why do GABA-sensitive pathways support regulation in some metabolic settings, yet reinforce dysfunction in others? In obesity and type 2 diabetes mellitus (T2DM), nutrient excess, insulin resistance, and chronic inflammation remodel the cellular environments in which GABA is produced, sensed, and metabolized. As a result, GABA signaling may shift from adaptive regulation that maintains tissue function to compensatory responses that attempt to limit metabolic stress, and ultimately to maladaptive outputs that reinforce disease progression. Here, we review the biochemical basis, sources, receptor systems, and extracellular regulation of peripheral GABA signaling. We then examine how GABA-sensitive pathways are organized across metabolic tissues and remodeled in obesity and T2DM, with emphasis on islet endocrine dysfunction, hepatic GABA output, and adipose-immune-microbiota interactions. We further consider how this framework informs pathway-specific therapeutic strategies and the barriers to translation. We propose that peripheral GABA signaling is neither inherently protective nor harmful. Its metabolic consequence depends on the source of GABA, the responding tissue environment, and the stage of metabolic disease.

Indexed as

Adaptation, PhysiologicalDiabetes Mellitus, Type 2gamma-Aminobutyric AcidSignal TransductionAnimalsHumansInsulin ResistanceObesitygamma-Aminobutyric Acidinsulin resistanceinter-organ communicationmetabolic adaptationmetabolic maladaptationobesityperipheral GABA signalingtype 2 diabetes mellitusγ-aminobutyric acid (GABA)

Identifiers

PMID42653146
PMCPMC13513948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.